AKR1B10 is an enzyme belonging to the aldo-keto reductase superfamily, a group of proteins involved in the reduction of aldehydes and ketones and in the regulation of cellular responses to oxidative stress. The enzyme has been associated with lipid metabolism, detoxification processes and the handling of reactive carbonyl compounds. In several cancers, including liver tumors, altered AKR1B10 expression has been linked to changes in cellular metabolism and tumor biology, making it a candidate biomarker for translating molecular changes inside a tumor into a measurable signal in the bloodstream.

The clinical appeal of a serum marker is straightforward: blood testing is less invasive and easier to repeat than tissue sampling or imaging. At present, alpha-fetoprotein, commonly known as AFP, is widely used in HCC assessment, but its sensitivity and specificity are not sufficient for every patient. Some tumors produce little or no AFP, while elevated levels can also occur in non-cancerous liver conditions. Researchers have therefore continued to search for complementary markers that can improve diagnostic confidence, particularly in people with cirrhosis or chronic hepatitis, where distinguishing malignant from non-malignant changes can be difficult.

The new study focuses on whether AKR1B10 can provide clinically useful information in serum. Measuring a protein or enzyme in blood requires more than demonstrating that it is present: researchers must determine whether its concentration differs meaningfully between patients with HCC and appropriate comparison groups. They must also assess how consistently the marker identifies disease, how frequently it produces false-positive results, and whether it adds information beyond established tests such as AFP, liver-function measurements and imaging examinations.

The investigators also examined AKR1B10 in the immediate postoperative setting, an area with particular importance for liver cancer care. Surgical removal of a tumor can produce a rapid change in the concentration of tumor-associated molecules circulating in the blood. If AKR1B10 levels fall after a complete resection, that pattern could support the interpretation that the main source of the marker has been removed. Conversely, persistently high or unexpectedly rising levels might indicate residual tumor tissue, early recurrence or biological information that warrants closer clinical evaluation.

Postoperative monitoring is challenging because surgery itself causes inflammation, tissue injury and temporary changes in liver function. These effects can influence blood-based measurements and complicate the interpretation of any single result. For that reason, a marker intended for immediate monitoring must be evaluated in relation to timing, baseline concentration and the patient’s clinical condition. Serial measurements may be more informative than one postoperative value, as trends can reveal whether a biomarker is moving in the direction expected after tumor removal.

AKR1B10 could be biologically relevant to HCC because malignant liver cells often undergo profound metabolic reprogramming. Tumor cells alter the way they process lipids, carbohydrates and reactive molecules in order to sustain rapid growth and survive under stress. An enzyme involved in carbonyl metabolism and oxidative-stress control may therefore reflect more than the presence of a mass; it may also mirror the biochemical state of the tumor. However, a plausible mechanism does not by itself establish clinical usefulness. The value of AKR1B10 must ultimately be determined by carefully measured diagnostic performance and by evidence that testing changes patient management.

The study’s findings are positioned within a broader effort to develop more precise, minimally invasive tools for HCC care. A useful biomarker could help clinicians identify patients who need additional imaging, support decisions about treatment, and provide an early indication of how the disease is responding after surgery. It could be particularly valuable when used alongside AFP rather than as a replacement, since combining markers that reflect different aspects of tumor biology can sometimes improve diagnostic accuracy. The practical impact would depend on assay standardization, reproducibility between laboratories and confirmation in larger, independent patient populations.

The researchers’ evaluation of AKR1B10 therefore addresses two linked clinical questions: whether the enzyme can help distinguish HCC from other liver conditions before treatment, and whether its serum concentration changes in a clinically interpretable way after tumor removal. If validated, AKR1B10 could become part of a broader surveillance strategy combining blood biomarkers, radiological imaging and clinical assessment. Such an approach would not eliminate the need for specialist evaluation, but it could offer a faster and more repeatable window into tumor status.

The work highlights the continuing shift in cancer diagnostics from single, imperfect indicators toward integrated molecular monitoring. For patients with HCC, the ultimate goal is not simply to discover a marker that is elevated in cancer, but to develop a test that improves decisions across the patient journey—from initial detection to postoperative surveillance and the recognition of possible recurrence. AKR1B10 now represents a candidate for that process. Its future clinical role will depend on further validation, particularly studies that compare it directly with AFP, test it across diverse liver-disease populations and determine whether AKR1B10-guided monitoring improves outcomes.

Subject of Research: Aldo-keto reductase 1B10 (AKR1B10) as a serum biomarker for hepatocellular carcinoma diagnosis and immediate postoperative monitoring.

Article Title: AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma.

Article References: Xie, M., Ye, X., Yu, Q. et al. AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03530-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41416-026-03530-x

Keywords: AKR1B10, hepatocellular carcinoma, liver cancer, serum biomarker, cancer diagnosis, postoperative monitoring, AFP, oncology, liver disease, biomarker research

Cancer metastasis, the process by which malignant cells spread from an original tumor site to distant organs, complicates treatment and often worsens prognoses. Specifically, when colorectal cancer cells invade the liver, they can present diagnostic challenges that conventional imaging or histopathological techniques may not adequately resolve. The UC San Diego team approached this challenge through the lens of microbial genomics, delving into the microbial DNA fragments circulating freely in the bloodstream, known as cell-free DNA (cfDNA). These microbial traces are remnants of microbial populations intimately linked with body tissue microenvironments and pathological states.

The researchers conducted their study on cfDNA isolated from the blood plasma of patients diagnosed with either primary liver cancer or metastatic colorectal cancer involving the liver. Utilizing advanced metagenomic sequencing methods, they profiled the microbial DNA present, revealing unique microbial ecosystems associated with each cancer type. Strikingly, they found that a microbial cfDNA classifier could distinguish between primary liver tumors and metastatic colorectal tumors in the liver with an impressive 90% accuracy, demonstrating a robust discriminatory power well beyond current non-invasive diagnostic benchmarks.

Further scrutiny of the microbial profiles uncovered that primary liver cancer patients demonstrated an abundance of specific bacterial species including Pseudomonas aeruginosa, Corynebacterium accolens, and Corynebacterium glucuronolyticum. These microbes are historically known to be associated with immunocompromised states, complications following liver transplantation, and host antimicrobial defense mechanisms. Their elevated presence hints at an altered immunological and microbial landscape intrinsic to liver tumor biology, potentially reflecting tumor microenvironment dynamics or immune evasion strategies.

Conversely, patients harboring metastatic colorectal cancer exhibited a distinct microbial signature dominated by various Acinetobacter species—including Acinetobacter tandoii, A. tianfuensis, A. septicus, and A. parvus—alongside Pseudomonas asiatica and Bifidobacterium faecale. These bacterial taxa have been implicated in hospital-acquired infections, bloodstream infections, and gastrointestinal inflammatory processes. Their association with metastatic disease underlines a possible link between systemic microbial translocation, inflammatory cascades, and cancer cell dissemination, suggesting that metastatic niches may foster or be influenced by specific microbial populations.

This pioneering research sheds light on the intricate connections between tumor biology and the human microbiome, particularly the circulating microbiome detectable through cfDNA analysis. The researchers emphasize that this microbial DNA signature approach operates independently of artificial intelligence or machine learning algorithms, relying instead on metagenomic characterization and classical bioinformatic classifiers. Such simplicity enhances the clinical scalability and translational potential of this diagnostic tool in diverse healthcare settings.

While the study cohort was modest, encompassing 27 patients, the implications are profound, advocating for expanded investigations to validate the microbial cfDNA signature across larger populations and diverse cancer types. Moreover, this line of inquiry dovetails with emerging recognition of the microbiome as a functional player in oncogenesis, tumor progression, and therapeutic responses, challenging conventional paradigms that often neglect microbial factors in cancer pathology.

Clinically, microbial cfDNA profiling could pave the way for novel, minimally invasive diagnostics that complement or even surpass imaging modalities, especially in cases where radiographic findings are ambiguous or inaccessible. Beyond diagnosis, such microbial fingerprints could serve as biomarkers for early cancer detection, prognostic assessment, or real-time monitoring of high-risk individuals, opening new avenues for microbiome-informed precision medicine.

From a therapeutic perspective, understanding microbial compositions uniquely associated with specific tumor types offers tantalizing prospects for microbiome-targeted interventions. Modulation of microbial communities through antibiotics, probiotics, or microbiota transplantation might become adjunct strategies to enhance cancer treatment efficacy or mitigate adverse immune reactions, particularly in immunocompromised patients or those undergoing transplantation.

The research, published in the peer-reviewed journal eGastroenterology on August 14, 2025, represents a multidisciplinary effort supported by the Prevent Cancer Foundation, the National Cancer Institute, and UC San Diego Moores Cancer Center. This study highlights UC San Diego’s leadership in integrating microbiology, oncology, and genomics to unravel the complexities of cancer biology through innovative technological approaches.

As research continues to elucidate the role of the microbiome in human health and disease, this study exemplifies how microbial signatures can transcend traditional diagnostic barriers, offering new hope for personalized cancer management. Future explorations will need to address how microbial DNA signatures evolve throughout cancer treatment courses, their interactions with host immune systems, and their potential as therapeutic targets or resistance markers.

The discovery also prompts reconsideration of microbial DNA’s origin—whether these microbes reside within tumor microenvironments, translocate systemically due to compromised barriers, or reflect broader host-microbe dynamics—that could influence tumor behavior and patient outcomes. Integrative multi-omics analyses combining microbial genomics, host transcriptomics, and metabolomics may be crucial in unraveling these complex interplays.

In summary, the identification of a plasma-based microbial DNA signature that distinguishes primary liver cancer from metastatic colorectal cancer represents a significant advancement in cancer diagnostics. This non-invasive approach not only enhances diagnostic precision but also establishes a foundation for leveraging microbial ecology in the ongoing battle against cancer, underscoring the microbial dimension of oncology’s future.

Subject of Research: Microbial DNA signatures in blood plasma as diagnostic biomarkers for differentiating primary liver cancer from metastatic colorectal cancer.

Article Title: Microbial DNA in Blood Plasma Distinguishes Primary Liver Cancer from Metastatic Colorectal Cancer with High Accuracy

News Publication Date: August 14, 2025

Web References:
http://dx.doi.org/10.1136/egastro-2025-100193

References: Published in eGastroenterology, August 14, 2025

Image Credits: Not provided

Keywords: Microbiota, Genetics, Cancer